641 related articles for article (PubMed ID: 32327175)
1. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
[TBL] [Abstract][Full Text] [Related]
2. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
3. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.
Romero A; Serna-Blasco R; Calvo V; Provencio M
Curr Treat Options Oncol; 2021 Aug; 22(10):86. PubMed ID: 34424428
[TBL] [Abstract][Full Text] [Related]
4. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
5. Single tube liquid biopsy for advanced non-small cell lung cancer.
de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
9. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.
García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB
Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327
[TBL] [Abstract][Full Text] [Related]
10. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
Scilla KA; Rolfo C
Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
Diao Z; Han Y; Zhang R; Li J
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy: unlocking the potentials of cell-free DNA.
Chu D; Park BH
Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
Fiala C; Diamandis EP
Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
[TBL] [Abstract][Full Text] [Related]
16. Enrichment and Analysis of ctDNA.
Gilson P
Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
[TBL] [Abstract][Full Text] [Related]
17. The role of circulating free DNA in the management of NSCLC.
Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
[TBL] [Abstract][Full Text] [Related]
18. Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.
Al-Obeidi E; Riess JW; Malapelle U; Rolfo C; Gandara DR
Hematol Oncol Clin North Am; 2023 Jun; 37(3):475-487. PubMed ID: 37024388
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
Cirillo M; Craig AFM; Borchmann S; Kurtz DM
Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
[TBL] [Abstract][Full Text] [Related]
20. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
